1. Home
  2. HE vs WVE Comparison

HE vs WVE Comparison

Compare HE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hawaiian Electric Industries Inc.

HE

Hawaiian Electric Industries Inc.

HOLD

Current Price

$13.49

Market Cap

2.6B

Sector

Utilities

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$5.67

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HE
WVE
Founded
1891
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
HE
WVE
Price
$13.49
$5.67
Analyst Decision
Sell
Strong Buy
Analyst Count
2
16
Target Price
$13.25
$29.81
AVG Volume (30 Days)
1.9M
3.7M
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
106.32
N/A
EPS
0.18
N/A
Revenue
$3,086,896,000.00
$3,704,000.00
Revenue This Year
$7.00
N/A
Revenue Next Year
$4.06
$85.67
P/E Ratio
$74.67
N/A
Revenue Growth
N/A
149.43
52 Week Low
$10.20
$5.02
52 Week High
$17.33
$21.73

Technical Indicators

Market Signals
Indicator
HE
WVE
Relative Strength Index (RSI) 42.10 33.33
Support Level $13.15 $5.02
Resistance Level $13.93 $7.65
Average True Range (ATR) 0.33 0.37
MACD 0.05 -0.01
Stochastic Oscillator 57.23 1.67

Price Performance

Historical Comparison
HE
WVE

About HE Hawaiian Electric Industries Inc.

Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: